Acetazolamide in combination with SGLT2i in patients with volume overload and acute heart failure

Status

Not yet recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-513799-16-00

Enrollment

Registered

2025-01-15

Start date

Unknown

Completion date

Unknown

Last updated

2025-01-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Heart Failure

Brief summary

24-hour sodium excretion

Detailed description

24-hour volume output, Weight change, Congestion assessment according to the ADVOR protocol, Plasma volume changes, Changes in neurohormonal stimulation (renin, aldosterone), Changes in POCUS (Heart, IVC, lung, abdomen, JVP)

Interventions

DRUGJardiance 10 mg film-coated tablets

DRUGForxiga 10 mg film-coated tablets

DRUGDIAMOX parenteraal 500 mg poeder voor injectievloeistof

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
24-hour sodium excretion	—

Secondary

Measure	Time frame
24-hour volume output, Weight change, Congestion assessment according to the ADVOR protocol, Plasma volume changes, Changes in neurohormonal stimulation (renin, aldosterone), Changes in POCUS (Heart, IVC, lung, abdomen, JVP)	—

Countries

Belgium

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026